换一批
换一批A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
作者：
关键词
ADA(s), anti-drug antibody(ies)AE, adverse eventALP, alkaline phosphataseALT, alanine aminotransferaseANCOVA, analysis of covarianceAST, aspartate aminotransferaseCFB, change from baselineCTX-1, C-terminal telopeptide of type 1 collagenC–P, Child-PughDXA, dual-energy X-ray absorptiometryELF, enhanced liver fibrosisFGF21FGF21, fibroblast growth factor-21FGFR, fibroblast growth factor receptorGGT, gamma-glutamyltransferaseHDL-C, HDL-cholesterolHOMA-IR, homeostatic model assessment of insulin resistanceHPA, hypothalamic-pituitary-adrenalHbA1c, hemoglobin A1cINR, international normalized ratioIRT, interactive response technologyLDL-C, LDL-cholesterolLS, least squaresMELD, model for end-stage liver diseaseNAFLD, non-alcoholic fatty liver diseaseNAS, NAFLD activity scoreNASH, non-alcoholic steatohepatitisNAb, neutralizing antibodyNon-HDL-C, non-HDL-cholesterolP1NP, procollagen type-I N-terminal propeptideP3NP, procollagen type III N-terminal propeptidePAI-1, plasminogen activator inhibitor-1Pro-C3, N-terminal type III collagen propeptideTEAE, treatment-emergent adverse eventTIMP-1, tissue inhibitor of metalloproteinase-1ULN, upper limit of normalcirrhosisclinical trialefruxiferminhistopathologyhs-CRP, high-sensitivity C-reactive proteinliver diseasenon-alcoholic steatohepatitis/NASHnonalcoholic fatty liver disease/NAFLD
DOI
10.1016/j.jhepr.2022.100563
PMID
36644237
发布时间
2023-01-17
- 浏览1
JHEP reports
2023年5卷1期
100563页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
